You can buy or sell LOGC and other stocks, options, and ETFs commission-free!
LogicBio Therapeutics, Inc. Common Stock, also called LogicBio Therapeutics, is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA. The listed name for LOGC is LogicBio Therapeutics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 15